Mitomics enters licensing agreement with QDx Pathology Services for QPredict Prostate Mitomic Test
April 02, 2016
Mitomics also today provided this update on the launch of PCMT in the United States:
"The urology community has acknowledged there is a clear unmet need for an additional tool to manage the negative biopsy patient," said Chris Merritt, vice president of sales and marketing, Mitomics. "As a result, our direct sales efforts to date have been very successful; we have begun to process tests, report results and continue to receive a favorable response from the market. The early adopters of PCMT are not only valuing the opportunity to know more from their original biopsy cores, but also utilizing the additional clinical data point to make subsequent biopsy decisions with confidence."
Prostate cancer is the most commonly diagnosed cancer in males and the second leading cause of cancer death in the United States. Every year, more than 230,000 American men are diagnosed with prostate cancer, and about 30,000 die from the disease. If detected early, prostate cancer is often treatable. It is estimated that well over 1 million prostate biopsies are performed annually in the United States, and although approximately 70 percent of all initial prostate biopsies are negative, it has been found that anywhere from 25 to 60 percent of these are positive on second or subsequent biopsy.